Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis
Journal of Bone and Mineral Metabolism · 2025-01 · 43 (1) · 3-9
DOI: 10.1007/s00774-024-01536-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Bone and Mineral Metabolism, online erschienen am 15.07.2024. Verfasst von Kosuke Ebina und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan. k-ebina@ort.med.osaka…. Hauptthemen laut MEDLINE: Parathyroid Hormone-Related Protein, Teriparatide, Osteoporosis, Postmenopausal, Antibodies, Monoclonal. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Osaka University.
Abstract (Originalsprache)
In the management of osteoporosis, anti-resorptive agents serve as a primary therapeutic approach. However, in cases where individuals exhibit an increased susceptibility to fractures, such as those characterized by severe low bone mass or a history of vertebral or hip fractures that markedly diminish life expectancy, the immediate reduction of fracture risk through the administration of osteoanabolic agents could be beneficial. Teriparatide, available in daily, once-weekly, or twice-weekly dosages, along with abaloparatide and romosozumab, constitutes a trio of such agents. Each of these medications is defined by unique characteristics, distinct efficacy profiles, and specific adverse effects. There is growing evidence to suggest that these agents have a superior effect on enhancing bone mineral density and reducing fracture incidence when compared to traditional bisphosphonate therapies. Nonetheless, their employment demands thorough consideration of clinical indications, which includes evaluating economic factors, the frequency of injections required, and the potential for adverse effects. The objective of this review is to consolidate the current evidence focusing primarily on the efficacy of these agents, with the goal of enhancing understanding and aiding in making more informed treatment decisions, particularly for those individuals who are at an elevated risk of fractures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan. k-ebina@ort.med.osaka-u.ac.jp.
- Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan. k-ebina@ort.med.osaka-u.ac.jp.
- Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
- Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
- Department of Health and Sport Sciences, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Förderung
- Osaka University
Zitieren
APA
Ebina, K., Etani, Y., Noguchi, T., Nakata, K., & Okada, S. (2025). Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis. Journal of Bone and Mineral Metabolism, 43(1), 3-9. https://doi.org/10.1007/s00774-024-01536-0
Vancouver
Ebina K, Etani Y, Noguchi T, Nakata K, Okada S. Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis. Journal of Bone and Mineral Metabolism. 2025;43(1):3-9. doi:10.1007/s00774-024-01536-0
BibTeX
@article{Ebina2025,
author = {Ebina, Kosuke and Etani, Yuki and Noguchi, Takaaki and Nakata, Ken and Okada, Seiji},
title = {Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis},
journal = {Journal of Bone and Mineral Metabolism},
year = {2025},
volume = {43},
number = {1},
pages = {3--9},
doi = {10.1007/s00774-024-01536-0}
}
EUVIMED